Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-10
DOI
10.1038/s41467-021-22875-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dual inhibition of MEK and AXL targets tumor cell heterogeneity and prevents resistant outgrowth mediated by the epithelial-to-mesenchymal transition in NSCLC
- (2021) Jessica M Konen et al. CANCER RESEARCH
- Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer
- (2020) Jae-Won Cho et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism
- (2019) David H. Peng et al. Science Translational Medicine
- The Combination of MEK inhibitor with Immunomodulatory Antibodies Targeting PD-1 and PD-L1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer
- (2019) Jong Woo Lee et al. Journal of Thoracic Oncology
- Commensal Microbiota Promote Lung Cancer Development via γδ T Cells
- (2019) Chengcheng Jin et al. CELL
- Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
- (2019) M D Hellmann et al. ANNALS OF ONCOLOGY
- Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures
- (2019) Carminia Maria Della Corte et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
- (2019) Cathy Eng et al. LANCET ONCOLOGY
- Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
- (2019) Ryan J. Sullivan et al. NATURE MEDICINE
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade
- (2018) Limo Chen et al. Cancer Discovery
- PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production
- (2018) Lindsay J. Celada et al. Science Translational Medicine
- Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer
- (2017) Pasi A. Jänne et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade
- (2017) Esra A. Akbay et al. Journal of Thoracic Oncology
- Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis.
- (2017) M. K. Callahan et al. JOURNAL OF CLINICAL ONCOLOGY
- Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma
- (2016) Y. Lou et al. CLINICAL CANCER RESEARCH
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report
- (2016) Marc Uemura et al. Journal of Hematology & Oncology
- A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
- (2015) G. R. Blumenschein et al. ANNALS OF ONCOLOGY
- An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2
- (2015) R. J. G. Cardnell et al. CLINICAL CANCER RESEARCH
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition
- (2015) M. P. Mak et al. CLINICAL CANCER RESEARCH
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- (2015) Matthew E. Ritchie et al. NUCLEIC ACIDS RESEARCH
- The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review
- (2015) Simone Punt et al. OncoImmunology
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
- (2014) Limo Chen et al. Nature Communications
- Th17 Cells in Cancer: The Ultimate Identity Crisis
- (2014) Stefanie R. Bailey et al. Frontiers in Immunology
- Essentials of Th17 cell commitment and plasticity
- (2013) P. Muranski et al. BLOOD
- Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators
- (2013) Yuanxiang Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
- (2012) Zhao Chen et al. NATURE
- TGF-β in Th17 Cell Development: The Truth Is Out There
- (2011) Robin D. Hatton IMMUNITY
- IL-6: Regulator of Treg/Th17 balance
- (2010) Akihiro Kimura et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers
- (2010) Bryan T. Hennessy et al. Clinical Proteomics
- IL-17 and Th17 Cells
- (2009) Thomas Korn et al. Annual Review of Immunology
- Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression
- (2009) D. L. Gibbons et al. GENES & DEVELOPMENT
- Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
- (2009) Michel DuPage et al. Nature Protocols
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started